Literature DB >> 3498743

Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study.

M Bergström1, C Muhr, P O Lundberg, K Bergström, A D Gee, K J Fasth, B Långström.   

Abstract

Four patients with prolactin-secreting pituitary adenomas were examined with positron emission tomography using L-[11C]methionine to monitor the effect of dopamine agonist treatment on the amino acid metabolism in the tumors. Within the first few hours after intramuscular injection of bromocriptine retard (50 mg) the amino acid metabolism decreased by 40%. Two of the patients were reexamined 7 and 9 days later and showed a 70% reduction in the metabolism of the adenomas. This metabolic effect was later accompanied by significant tumor shrinkage in all adenomas. It is suggested that bromocriptine has a general and rapid effect on the protein synthesis of the prolactin-secreting pituitary adenoma cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498743     DOI: 10.1097/00004728-198709000-00014

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  9 in total

Review 1.  Positron emission tomography applied in the study of pituitary adenomas.

Authors:  C Muhr; M Bergström
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

2.  Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery.

Authors:  Yingxiao Cao; Fengju Wang; Zhenbo Liu; Baohua Jiao
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

3.  11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.

Authors:  B N T Tang; M Levivier; M Heureux; D Wikler; N Massager; D Devriendt; P David; N Dumarey; B Corvilain; S Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-15       Impact factor: 9.236

4.  Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study.

Authors:  K Kubota; S Yamada; K Ishiwata; M Ito; T Fujiwara; H Fukuda; M Tada; T Ido
Journal:  Eur J Nucl Med       Date:  1993-06

5.  PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment.

Authors:  B J Daemen; R Zwertbroek; P H Elsinga; A M Paans; H Doorenbos; W Vaalburg
Journal:  Eur J Nucl Med       Date:  1991

Review 6.  The applications of positron emission tomography to oncology.

Authors:  R J Ott
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

7.  11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy.

Authors:  W A Bashari; M van der Meulen; J MacFarlane; D Gillett; R Senanayake; L Serban; A S Powlson; A M Brooke; D J Scoffings; J Jones; D G O'Donovan; J Tysome; T Santarius; N Donnelly; I Boros; F Aigbirhio; S Jefferies; H K Cheow; I A Mendichovszky; A G Kolias; R Mannion; O Koulouri; M Gurnell
Journal:  Pituitary       Date:  2022-05-24       Impact factor: 3.599

8.  Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery.

Authors:  Leontine E H Bakker; Marco J T Verstegen; Wouter R van Furth; Lenka M Pereira Arias Bouda; Eidrees Ghariq; Berit M Verbist; Pieter J Schutte; Waiel A Bashari; Mark C Kruit; Alberto M Pereira; Mark Gurnell; Nienke R Biermasz
Journal:  Pituitary       Date:  2022-05-26       Impact factor: 3.599

9.  Carbon-11-methionine and PET in evaluation of treatment response of breast cancer.

Authors:  R Huovinen; S Leskinen-Kallio; K Någren; P Lehikoinen; U Ruotsalainen; M Teräs
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.